OTC Markets OTCPK - Delayed Quote USD

Wewards, Inc. (WEWA)

2.2000

+2.2000

(0.00%)

At close: May 27 at 4:00:00 PM EDT

Costco posts mixed earnings results as consumers seek value amid tariff uncertainty

Costco posts earnings growth as the company navigates an uncertain macro landscape.

Yahoo Finance 11 hours ago

COST
Costco earnings top estimates despite tariffs

Costco (COST) reported third quarter earnings of $4.28 per share compared to the Bloomberg consensus estimate of $4.24. Revenue was $63.21 billion versus an estimated $63.31 billion. Comparable sales, excluding gas and currency impacts, were up 8%. Analysts had anticipated 6.99%. Market Domination Overtime Anchors Julie Hyman and Josh Lipton are joined by Senior Reporter Brooke DiPalma to discuss the results. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 12 hours ago

COST
Uber, Tesla robotaxis, Synopsys guidance: Trending Tickers

Uber (UBER) shares slide into negative territory on Thursday amid speculation around Tesla's (TSLA) rollout of robotaxis in Austin, Texas, on June 12. Catch Tesla investor Ross Gerber share his thoughts on Waymo's robotaxi model as compared to Tesla's plans. Synopsys (SNPS) suspends its guidance for its current fiscal third quarter and full-year 2025 as it digests new export controls on shipments to China. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 13 hours ago

TSLA

SNPS

UBER
This Company's CEO Said It Wants to Become the Nvidia of Quantum Computing. Should You Buy the Stock Now?

It's a bold statement, but if he's right, the stock would generate life-changing investment returns.

Motley Fool 35 minutes ago

NVDA

IONQ-WS
Bitcoin Price Falls. The House Just Introduced a New Crypto Bill.

Bitcoin price slipped even as major developments for the crypto industry look to be underway in the U.S.

Barrons.com 37 minutes ago

^GSPC

BTC-USD

ETH-USD
Sanofi, Regeneron shares nosedive after mixed Itepekimab results

Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab.

Investing.com 1 hour ago

SNY

REGN
Where Will Costco Stock Be in 5 Years?

Costco has built a near-unmatched empire in retail. Costco (NASDAQ: COST) has been one of the most dominant retailers in modern history. While Costco faces competition in the category from BJ's Wholesale and Walmart's Sam's Club, Costco is the clear leader in warehouse retail.

Motley Fool 1 hour ago

COST
Sanofi, Regeneron’s Itepekimab Delivers Mixed Results in Late-Stage Trials

Sanofi and Regeneron said that drug candidate didn’t meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.

The Wall Street Journal 2 hours ago

REGN

SNY

SNYNF
UiPath Inc (PATH) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

UiPath Inc (PATH) reports a 12% increase in ARR and significant improvements in operating income, while navigating a variable macroeconomic environment.

GuruFocus.com 2 hours ago

PATH
Marvell Technology Inc (MRVL) Q1 2026 Earnings Call Highlights: Record Revenue and Robust AI ...

Marvell Technology Inc (MRVL) reports a 63% year-over-year revenue increase, driven by strong data center performance and strategic business moves.

GuruFocus.com 2 hours ago

MRVL
Dell Technologies Inc (DELL) Q1 2026 Earnings Call Highlights: Strong AI Server Demand and ...

Dell Technologies Inc (DELL) reports robust growth in AI server orders and cash flow, despite a decline in consumer revenue and competitive pressures.

GuruFocus.com 2 hours ago

DELL
Costco Wholesale Corp (COST) Q3 2025 Earnings Call Highlights: Strong Growth in Net Income and ...

Costco Wholesale Corp (COST) reports a 13% increase in net income and significant e-commerce growth, while navigating challenges from tariffs and inflation.

GuruFocus.com 2 hours ago

COST
Red Robin Gourmet Burgers Inc (RRGB) Q1 2025 Earnings Call Highlights: Strong Profit Margins ...

Despite a rise in menu prices boosting revenue, Red Robin Gourmet Burgers Inc (RRGB) faces hurdles with declining guest traffic and revised revenue guidance.

GuruFocus.com 2 hours ago

RRGB
Ulta Beauty Inc (ULTA) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures

Ulta Beauty Inc (ULTA) reports a 4.5% increase in net sales and expands its loyalty base, while navigating challenges in operating margins and market uncertainties.

GuruFocus.com 2 hours ago

ULTA
Zscaler Inc (ZS) Q3 2025 Earnings Call Highlights: Strong Growth Amid Economic Challenges

Zscaler Inc (ZS) reports robust revenue and ARR growth, while navigating macroeconomic uncertainties and expanding its product portfolio.

GuruFocus.com 2 hours ago

ZS
Analyst Views Split on Marvell (MRVL) – Here’s What They’re Watching

We recently published a list of 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Marvell Technology, Inc. (NASDAQ:MRVL) stands against other AI stocks on Wall Street’s radar. On May 28, Stifel analyst Tore Svanberg reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with […]

Insider Monkey 3 hours ago

MRVL
Ulta Beauty, Inc. (ULTA): A Bull Case Theory

We came across a bullish thesis on Ulta Beauty, Inc. (ULTA) by @wallstengine on X (Twitter). In this article, we will summarize the bulls’ thesis on ULTA. Ulta Beauty, Inc. (ULTA)’s share was trading at $407.04 as of 23rd May. ULTA’s trailing and forward P/E were 16.06 and 17.89 respectively according to Yahoo Finance. Ulta Beauty (ULTA) […]

Insider Monkey 4 hours ago

ULTA
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did not meet the primary endpoint despite a benefit seen earlier in the trial Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials Regeneron and Sanofi are assessing the data and wi

GlobeNewswire 4 hours ago

REGN

SNY

SNYNF
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefitAERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the studyItepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2Sanofi and Regeneron are as

GlobeNewswire 4 hours ago

SNY

SNYNF
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

StockStory 4 hours ago

REGN

ZTS

ROST

Performance Overview

Return	WEWA	S&P 500 (^GSPC)
YTD	+4.46%	+0.52%
1-Year	+4.46%	+12.25%
3-Year	+8,340.00%	+42.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Wewards, Inc. (WEWA)

Related News

Costco posts mixed earnings results as consumers seek value amid tariff uncertainty

Costco earnings top estimates despite tariffs

Uber, Tesla robotaxis, Synopsys guidance: Trending Tickers

This Company's CEO Said It Wants to Become the Nvidia of Quantum Computing. Should You Buy the Stock Now?

Bitcoin Price Falls. The House Just Introduced a New Crypto Bill.

Sanofi, Regeneron shares nosedive after mixed Itepekimab results

Where Will Costco Stock Be in 5 Years?

Sanofi, Regeneron’s Itepekimab Delivers Mixed Results in Late-Stage Trials

UiPath Inc (PATH) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

Marvell Technology Inc (MRVL) Q1 2026 Earnings Call Highlights: Record Revenue and Robust AI ...

Dell Technologies Inc (DELL) Q1 2026 Earnings Call Highlights: Strong AI Server Demand and ...

Costco Wholesale Corp (COST) Q3 2025 Earnings Call Highlights: Strong Growth in Net Income and ...

Red Robin Gourmet Burgers Inc (RRGB) Q1 2025 Earnings Call Highlights: Strong Profit Margins ...

Ulta Beauty Inc (ULTA) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures

Zscaler Inc (ZS) Q3 2025 Earnings Call Highlights: Strong Growth Amid Economic Challenges

Analyst Views Split on Marvell (MRVL) – Here’s What They’re Watching

Ulta Beauty, Inc. (ULTA): A Bull Case Theory

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar

Performance Overview